Fluorine-18-fluorodeoxyglucose cardiac imaging using a modified scintillation camera

Journal of Nuclear Medicine

Volumn 39, Issue 12, 1998, Pages 2035-2043

  Sandler, Martin P ^a   Bax, Jeroen J ^b   Patton, James A ^b   Visser, Frans C ^b   Martin, William H ^b   Wijns, William ^b  

^a VANDERBILT UNIVERSITY   (United States)

^b NONE

Author keywords

Cardiac; Fluorodeoxyglucose; SPECT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; THALLIUM 201;

ARTICLE; COLLIMATOR; COST CONTROL; DIAGNOSTIC ACCURACY; HEART MUSCLE INJURY; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SCINTILLATION CAMERA;

EQUIPMENT DESIGN; FLUORODEOXYGLUCOSE F18; GAMMA CAMERAS; HEART; HUMANS; MYOCARDIAL ISCHEMIA; PHANTOMS, IMAGING; RADIOPHARMACEUTICALS; THALLIUM RADIOISOTOPES; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0032437165     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (71)

1. Tillisch J, Brunken R, Marshall R, et al. Reversibility of cardiac wall motion abnormalities predicted by positron tomography. N Engl J Med 1986;314:884-888.
2. Tamaki N, Yonekura Y, Yamashita K, et al. Positron emission tomography using fluoro-18 deoxyglucose in evaluation of coronary artery bypass grafting. Am J Cardiol 1989;64:860-865.
3. Nienaber CA, Brunken RC, Sherman CT, et al. Metabolic and functional recovery of ischemic human myocardium after coronary angioplasty. J Am Coll Cardiol 1991;18: 966-978.
4. Marwick TH, Nemec JJ, Lafont A, Salcedo EE, MacIntyre WJ. Prediction by postexercise fluoro-18-deoxyglucose positron emission tomography of improvement in exercise capacity after revascularization. Am J Cardiol 1992;69:854-859.
5. Lucignani G, Paolini G, Landoni C, et al. Presurgical identification of hibernating myocardium by combined use of technetium-99m hexakis 2-methoxyisobutylisonitrile single photon emission tomography and fluorine-18 fluoro-2-deoxy-D-glucose positron emission tomography in patients with coronary artery disease. Eur J Nucl Med 1992;19:874-881.
6. Carrel Y, Jenni R, Haubold-Reuter S, Schulthess G, Pasic M, Turina M. Improvement of severely reduced left ventricular function after surgical vascularization in patients with preoperative myocardial infarction. Eur J Cardiothorac Surg 1992;6:479-484.
7. Eitzman D, Al-Aouar Z, Kanter HL, et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol 1992;20:559-565.
8. Sandler MP, Patton JA. Fluorine 18-labeled fluorodeoxyglucose myocardial single-photon emission computed tomography: an alternative for determining myocardial viability. J Nucl Cardiol 1996;3:342-349.
9. Dilsizian V, Bonow RO. Current diagnostic techniques of assessing myocardial viability in patients with hibernating and stunned myocardium. Circulation 1993;87: 1-20.
10. Hoflin Ledermann H, Noelpp U, Weinreich R, Rosler H. Routine F-18-2-deoxy-2-fluoro-D-glucose (F-18-FDG) myocardial tomography using a normal large field of view gamma camera. Angiology 1989;40:1058-1064.
11. Williams KA, Taillon LA, Start VJ. Quantitative planar imaging of glucose metabolic activity in myocardial segments with exercise thallium-201 perfusion defects in patients with myocardial infarction: comparison with late (24-hour) redistribution thallium imaging for detection of reversible ischemia. Am Heart J 1992;124:294-304.
12. Lingen AV, Huijgens PC, Visser FC, et al. Performance characteristics of a 511-keV collimator for imaging positron emitters with a standard gamma-camera. Eur J Nucl Med 1992;19:315-321.
13. Bax JJ, Visser FC, Blanksma PK, et al. Comparison of myocardial uptake of F18-fluorodcoxyglucose imaged with positron emission tomography and single photon emission computed tomography. J Nucl Med 1996;37:1631-1636.
14. Stoll HP, Hellwin N, Alexander C, Ozbek C, Schieffer H, Oberhausen E. Myocardial metabolic imaging by means of fluorine-18 deoxyglucose/technetium-99m sestamibi dual-isotope single photon emission tomography. Eur J Nucl Med 1994;21:1085-1093.
15. Kalff V, Berlangieri SU, van Every B, et al. Is planar thallium 201/F-18 fiuorodeoxyglucose imaging a reasonable clinical alternative to PET myocardial viability scanning? Eur J Nucl Med 1995;22:625-632.
16. Martin WH, Delbeke D, Patton JA, et al. FDG SPECT: correlation with FDG-PET. J Nucl Med 1995;36:988-995.
17. Burt RW, Perkins OW, Oppenheim BE, et al. Direct comparison of fluorine-18-FDG SPECT, fluorine-18-FDG PET and rest thallium-201 SPECT for detection of myocardial viability. J Nucl Med 1995;36:176-179.
18. Huitink JM, Visser FC, van Lingen A, et al. Feasibility of planar fluorine-18-FDG imaging after recent myocardial infarction to assess myocardial viability. J Nucl Med 1995;36:975-981.
19. Bax JJ, Cornel JH, Visser FC, et al. Reversibility of wall motion abnormalities predicted by SPECT with F18-fluorodeoxyglucose. J Nucl Med 1994;35(suppl):136P.
20. Sandler MP, Videlefsky S, Delbeke D, et al. Evaluation of myocardial ischemia using a rest metabolism/stress perfusion protocol with fluorine-18 deoxyglucose/technetium-99m MIBI and dual-isotope simultaneous-acquisition single-photon emission computed tomography. J Am Coll Cardiol 1995;26:870-878.
21. Delbeke D, Videlefsky S, Patton JA, et al. Rest myocardial perfusion/metabolism imaging using simultaneous dual-isotope acquisition SPECT with technetium-99m-MIBI/fluorine-18-FDG. J Nucl Med 1995;36:2110-2119.
22. Patton JA, Sandler MP, Ohana I, Weinfeld Z. High-energy (511 keV) imaging with the scintillation camera. RadioGraphics 1996;16:1183-1194.
23. Yang DC, Ragasa E, Gould L, et al. Radionuclide simultaneous dual-isotope stress myocardial perfusion study using the "three window technique." Clin Nucl Med 1993;18:852-857.
24. Siegel S, Dahlbom M. Implementation and validation of a calculated attenuation correction for PET. IEEE Trans Nucl Sci 1992;39:1117-1121.
25. 18F-labeled fluorodeoxyglucose and N-13 ammonia. Circulation 1983;67:766-778.
26. Heyndrickx GR, Wijns W, Degrieck Y, Vandeplassche L, Melin JA. Recovery of regional contractile function and oxidative metabolism in stunned myocardium induced by 1-hour circumflex coronary artery occlusion in chronically instrumented dogs. Circ Res 1993;72:901-913.
27. Vanoverschelde JLJ, Wijns W, Depre C, et al. Mechanisms of chronic regional postischemic dysfunction in humans. New insights from the study of noninfarcted collateral-dependent myocardium. Circulation 1993;87:1513-1523.
28. Rechavia E, de Silva R, Kushwaha SS, et al. Enhanced myocardial F18-fluoro-2-deoxyglucose uptake after orthotopic heart transplantation assessed by positron emission tomography. J Am Coll Cardiol 1997;30:533-538.
29. 18F]2-deoxy-2-fluoro-D-glucose for assessing myocardial glucose uptake. Circulation 1995;91:2435-2444.
30. Sun D, Nguyen N, DeGrado TR, Schwaiger M, Brosius III FC. Ischemia induces translocation of the insulin-responsive glucose transporter GLUT4 to the plasma membrane of cardiac myocytes. Circulation 1994;89:793-798.
31. Camici RG, Ferrannini E, Opie LH. Myocardial metabolism in ischemic heart disease: basic principles and application to imaging by positron emission tomography. Prog Cardiovasc Dis 1989;32:217-238.
32. Nuutila P, Koivisto VA, Knuuti J, et al. Glucose-free fatty acid cycle operates in human heart and skeletal muscle in vivo. J Clin Invest 1992;89:1767-1774.
33. Black HR. The coronary artery disease paradox: the role of hyperinsulinemia and insulin resistance and implications for therapy. J Cardiovasc Pharmacol 1990; 15(suppl):S26-S38.
34. Bennett PH. Definition, diagnosis, and classification of diabetes mellitus and impaired glucose tolerance. In: Kahn CR, Weir GC, eds. Joslin's diabetes mellitus, 13th ed. Malvern, PA: Lea & Febiger; 1994:193-200.
35. Rogers WJ, Russell RO, McDaniel HG, Rackley CE. Acute effects of glucose-insulin-potassium infusion on myocardial substrates, coronary blood flow and oxygen consumption in man. Am J Cardiol 1977;40:421-428.
36. Martin WH, Jones RC, Delbeke D, Sandler MP. A simplified intravenous glucose loading protocol for fluorine- 18-fluorodeoxyglucose cardiac single-photon emission tomography. Eur J Nucl Med 1997;24:1291-1297.
37. Vom Dahl J, Hicks R, Lee K, Eitzman D, Alaouar Z, Schwaiger M. Positron emission tomography myocardial viability studies in patients with diabetes mellitus. J Am Coll Cardiol 1991;17:121A.
38. Prellwitz J, Vasta M, Sunderland J, Shiue C-Y, Gupta N, Frick M. Investigation of factors influencing FDG myocardial image quality [Abstract]. J Nucl Med 1991;32: 1039.
39. Knuuti MJ, Nuutila P, Ruotsalainen U, et al. Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron emission tomography. J Nucl Med 1992;33:1255-1262.
40. Bax JJ, Visser FC, van Lingen A, et al. Feasibility of myocardial F18-fluorodeoxyglucose single photon emission computed tomography in patients with noninsulin-dependent diabetes mellitus. Nucl Med Commun 1997;18:200-206.
41. Ohtake T, Yokoyama I, Watanabe T, et al. Myocardial glucose metabolism in noninsulin-dependent diabetes mellitus patients evaluated by FDG-PET. J Nucl Med 1995;36:456-463.
42. Schelbert HR. Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron emission tomography. J Nucl Med 1992;33:1263-1266.
43. Knuuti MJ, Yki-Järvinen H, Voipio-Pulkki LM, et al. Enhancement of myocardial [fluorine-18] fluorodeoxyglucose uptake by a nicotinic acid derivative. J Nucl Med 1994;35:989-998.
44. Fuccella LM, Goldaniga GC, Lovisolo PP. Inhibition of lipolysis by nicotinic acid and by acipimox. Clin Pharmacol Ther 1980;28:790.
45. Musatti L, Maggi E, Moro E, Valzelli G, Tamassia V. Bioavailability and pharmacokinetics in man of acipimox, a new antilipolytic and hypolipemic agent. J Int Med Res 1981;9:381-386.
46. Knuuti H, Nuutila P, Ruotsalainen U, et al. Euglycemic hyperinsulinemic clamp and oral glucose load in stimulating myocardial glucose utilization during positron emission tomography. J Nucl Med 1992;33:1255-1262.
47. Bax JJ, Veening MA, Visser FC, et al. Optimal metabolic conditions during FDG imaging: a comparative study using different protocols. Eur J Nucl Med 1997;24:35-41.
48. Gropler RJ. Methodology governing the assessment of myocardial glucose metabolism by PET and fluorine 18-labeled FDG. J Nucl Cardiol 1994;1:S4-S14.
49. Bax JJ, Cornel JH, Visser FC, et al. Prediction of improvement of contractile function in patients with ischemic ventricular dysfunction after revascularization by F18-fluorodeoxyglucose SPECT. J Am Coll Cardiol 1997;39:377-384.
50. Patlak CS, Blasbeg RG. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data: generalizations. J Cereb Blood Flow Metab 1985;5:584-590.
51. Gambhir SS, Schwaiger M, Huang SC, et al. Simple noninvasive quantification method for measuring myocardial glucose utilization in humans employing positron emission tomography and fluorine-18 deoxyglucose. J Nucl Med 1989;30:359-366.
52. Porenta G, Kuhle W, Czernin J, et al. Semiquantitative assessment of myocardial blood flow and viability using polar map displays of cardiac PET images. J Nucl Med 1992;33:1623-1631.
53. 18F]fluorodeoxyglucose in patients with chronic coronary artery disease. A functional and morphological approach to the detection of residual myocardial viability. Circulation 1995;91:1006-1015.
54. Chan RKM, Lee KJ, Calafiore P, Berlangieri SU, McKay WJ, Tonkin AM. Comparison of dobutamine echocardiography and positron emission tomography in patients with chronic ischemic left ventricular dysfunction. J Am Coll Cardiol 1996;27:1601-1607.
55. Bax JJ, Wijns W, Cornel JH, Visser FC, Boersma E, Fioretti PM. Accuracy of currently available techniques for prediction of functional recovery after revascularization in patients with left ventricular dysfunction due to chronic coronary artery disease: comparison of pooled data. J Am Coll Cardiol 1997;30:1451-1460.
56. Vom Dahl J, Eitzman DT, Al-Aouar ZR, et al. Relation of regional function, perfusion and metabolism in patients with advanced coronary disease undergoing surgical revascularization. Circulation 1994;90:2356-2366.
57. Ritchie JL, Bateman TM, Bonow RO, et al. Guidelines for clinical use of cardiac radionuclide imaging. Circulation 1995;91:1278-1303.
58. Elefteriades JA, Tolis G, Levi E, Mills LK, Zaret BL. Coronary artery bypass grafting in severe left ventricular dysfunction: excellent survival with improved ejection fraction and functional state. J Am Coll Cardiol 1993;22:1411-1417.
59. Ross JR Jr. Myocardial perfusion-contraction matching: implications for coronary heart disease and hibernation. Circulation 1991;83:1076-1083.
60. Mock M, Ringqvist I, Fisher LD, et al. Survival of medically treated patients in the coronary artery surgery study (CASS) registry. Circulation 1982;66:562-568.
61. Maddahi J, Schelbert H, Brunken R, Di Carli M. Role of Tl-201 and PET imaging in evaluation of myocardial viability and management of patients with coronary artery disease and left ventricular dysfunction. J Nucl Med 1994;35:707-715.
62. Di Carli M, Davidson M, Little R, et al. Value of metabolic imaging with positron emission tomography for evaluating prognosis in patients with coronary artery disease and left ventricular dysfunction. Am J Cardiol 1994;73:527-533.
63. Eitzman D, Al-Aouar ZR, Kanter HL, et al. Clinical outcome of patients with advanced coronary artery disease after viability studies with positron emission tomography. J Am Coll Cardiol 1992;20:559-565.
64. Vom Dahl J, Altehoefer C, Sheehan FH, et al. Effect of myocardial viability assessed by technetium-99m-sestamibi SPECT and fluorine-18-FDG PET on clinical outcome in coronary artery disease. J Nucl Med 1997;38:742-748.
65. Marwick TH, MacIntyre WJ, Lafont A, Nemec JJ, Salcedo EE. Metabolic responses of hibernating and infarcted myocardium to revascularization. Circulation 1992;85:1347-1353.
66. Camici PG, Wijns W, Borgers M, et al. Pathophysiological mechanisms of chronic reversible left ventricle dysfunction due to coronary artery disease (hibernating myocardium). Circulation 1997;96:3205-3214.
67. Dilsizian V, Rocco TP, Freedman NMT, Leon MB, Bonow RO. Enhanced detection of ischemic but viable myocardium by the reinjection of thallium after stress-redistribution imaging. N Engl J Med 1990;323:141-146.
68. 201Tl imaging in detection of myocardial viability and prediction of improvement in left ventricular function after coronary bypass surgery in patients with severely depressed left ventricular function. Circulation 1993;87:1630-1641.
69. Bax JJ, Cornel JH, Visser FC, et al. Prediction of recovery of myocardial dysfunction after revascularization: comparison of fluorine-18 fluorodeoxyglucose/thallium-201 SPECT, thallium-201 stress-reinjection SPECT and dobutamine echocardiography. J Am Coll Cardiol 1996;28:558-565.
70. Bax JJ, Cornel JH, Visser FC, Fioretti PM, van Lingen A, Visser CA. Comparison of thallium-201 rest-redistribution SPECT and FDG SPECT in predicting functional recovery after revascularization. J Am Coll Cardiol 1996;27(suppl A):300A.
71. Cornel JH, Bax JJ, Fioretti PM. Assessment of myocardial viability by dobutamine stress echocardiography. Curr Opin Cardiol 1996;11:621-626.